Research Analysts Issue Forecasts for ACADIA Pharmaceuticals Inc.’s FY2025 Earnings (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at Zacks Research decreased their FY2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a note issued to investors on Monday, April 22nd. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will earn $0.93 per share for the year, down from their prior estimate of $0.94. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.62 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ Q1 2026 earnings at $0.41 EPS and FY2026 earnings at $1.28 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported $0.28 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The business had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The company’s revenue was up 69.3% on a year-over-year basis.

Several other equities analysts have also issued reports on ACAD. Oppenheimer reaffirmed a “market perform” rating and set a $25.00 price objective on shares of ACADIA Pharmaceuticals in a report on Monday, February 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, April 9th. JMP Securities reaffirmed a “market outperform” rating and set a $42.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 7th. Finally, JPMorgan Chase & Co. decreased their target price on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, March 25th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.82.

ACADIA Pharmaceuticals Stock Down 0.9 %

NASDAQ:ACAD opened at $16.59 on Tuesday. The stock’s fifty day moving average is $20.47 and its two-hundred day moving average is $23.69. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -43.66 and a beta of 0.37. ACADIA Pharmaceuticals has a 52 week low of $16.55 and a 52 week high of $33.99.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Several institutional investors have recently modified their holdings of the company. Empire Life Investments Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 0.3% during the 4th quarter. Empire Life Investments Inc. now owns 174,815 shares of the biopharmaceutical company’s stock worth $5,473,000 after buying an additional 467 shares during the last quarter. Handelsbanken Fonder AB increased its holdings in shares of ACADIA Pharmaceuticals by 2.3% during the 4th quarter. Handelsbanken Fonder AB now owns 31,633 shares of the biopharmaceutical company’s stock worth $990,000 after buying an additional 700 shares during the last quarter. Franklin Resources Inc. increased its holdings in shares of ACADIA Pharmaceuticals by 1.6% during the 4th quarter. Franklin Resources Inc. now owns 50,405 shares of the biopharmaceutical company’s stock worth $1,578,000 after buying an additional 803 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter worth $39,000. Finally, Phocas Financial Corp. increased its holdings in shares of ACADIA Pharmaceuticals by 1.9% during the 4th quarter. Phocas Financial Corp. now owns 66,957 shares of the biopharmaceutical company’s stock worth $2,096,000 after buying an additional 1,266 shares during the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Insider Activity at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 1,790 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $31,987.30. Following the completion of the sale, the insider now owns 13,100 shares in the company, valued at $234,097. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider James Kihara sold 1,790 shares of the firm’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $17.87, for a total value of $31,987.30. Following the completion of the sale, the insider now owns 13,100 shares in the company, valued at $234,097. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Stephen Davis sold 5,577 shares of the business’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $24.67, for a total value of $137,584.59. Following the sale, the chief executive officer now directly owns 101,890 shares in the company, valued at approximately $2,513,626.30. The disclosure for this sale can be found here. Insiders sold a total of 69,383 shares of company stock worth $1,291,362 over the last 90 days. Company insiders own 27.50% of the company’s stock.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.